Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical TrialsJeff Sevigny, Jerome Barakos, Joyce Suhy et al.|Alzheimer Disease & Associated Disorders|2016Cited by 115
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumabChristopher Carlson, Jerome Barakos, Wahiba Estergard et al.|Alzheimer s & Dementia|2011Cited by 76
Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's diseaseChristopher Carlson, Jerome Barakos, Eric Siemers et al.|Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring|2016Cited by 65
P4‐472: Vasogenic edema in the setting of ß‐amyloid lowering therapy, adverse event: what is it and how is it detected?Jerome Barakos, Eric Siemers, Joonmi Oh et al.|Alzheimer s & Dementia|2011Cited by 3
P1‐252: CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTSGregory Klein, Joyce Suhy, Ping Chiao et al.|Alzheimer s & Dementia|2014Cited by 2